MAM
MASS APPEAL AND UNIVERSAL MUSIC INDIA TO LAUNCH MASS APPEAL INDIA
Mumbai: Mass Appeal, the urban culture-focused entertainment company, and Universal Music Group (UMG), the world leader in music-based entertainment, today announced the launch of Mass Appeal India – an innovative new label dedicated to amplifying India’s burgeoning hip-hop culture on a global scale.
Mass Appeal India’s operations will be based in Mumbai, within Universal Music India’s (UMI) headquarters and will function as a multi-channel partnership between the two companies. Mass Appeal India will sign and collaborate with the brightest stars from India’s fastest growing music scene and, through Mass Appeal’s global network, will work with brands and content creators to connect the culture with a worldwide audience.
Mass Appeal India will leverage UMI’s marketing and promotion teams within India, whilst Mass Appeal will lead release strategy within the U.S. and Canada. All releases from Mass Appeal India will be distributed exclusively via UMG worldwide, with additional support across its network of more than 60 territories for select artists and projects.
To coincide with its launch, the label has announced the marquee signing of India’s most popular and acclaimed rapper DIVINE. Central to the rise of the ‘gully rap’ movement, with hit singles like ‘Meri Gully Mein’, ‘Jungli Sher’ and ‘Kaam 25’, DIVINE’s brutally honest Hindi rap draws inspiration from his own life and the streets of Mumbai, set to beats that wouldn’t be out of place in a Los Angeles or New York studio. His single ‘Jungli Sher’ was the first Indian single that Apple Music released worldwide. DIVINE was also the first Indian artist to be featured on BBC 1 Xtra’s ‘Fire In The Booth’ in 2016.
In announcing the launch of Mass Appeal India, Nas said, “I was first introduced to DIVINE’s music through the brilliant film Gully Boy. I’m proud to announce the launch of Mass Appeal India with DIVINE as the first artist on our roster. Hip-hop is the world’s most influential culture – it’s only right to share what we do at Mass Appeal on a global level. We’re excited about joining forces with the team at UMG India to help further spark a movement that is constantly in the making.”
Devraj Sanyal, MD & CEO of UMG, India & South Asia said, “Over the past few years UMI has concentrated on creating a culture of artist-first, non-film music to satisfy India’s rapidly evolving music audience. Hip-hop has been a key area of this focus and we have found the natural partner in Mass Appeal, Nas & Peter to help realise our dream of breaking Indian hip-hop in the region, as well as to the rest of the world together. It was only right to lead this global announcement with the signing of India’s number one hip-hop star, DIVINE for his highly anticipated debut album. As he articulately puts it, “Apna time Aayega” which means, “our time will come” – now is certainly the time for Indian Hip-Hop to break into the mainstream.”
Peter Bittenbender, CEO of Mass Appeal, said, “Coming off what has been a landmark year for Mass Appeal, we are beyond thrilled to announce the global expansion of our brand in partnership with UMI and with DIVINE as our first superstar talent signing. This new venture is an incredibly exciting extension of Mass Appeal’s strategy to progress the conversation and landscape of hip hop by taking our brand to the most exciting global markets.”
DIVINE’s story and rise of the Indian hip-hop scene inspired Bollywood director Zoya Akhtar’s 2019 acclaimed feature film Gully Boy, starring Ranveer Singh, which has also become one of the year’s biggest Bollywood films at the box office. Gully Boy featured DIVINE in action on five tracks and has helped showcase both him and India’s explosive rap scene to new audiences around the world.
“It’s an honour to be associated with a legend like Nas. I grew up listening to his music. For him to recognise not just me, but the whole Indian hip-hop scene is a big win for hip-hop, and for hip-hop in India,” DIVINE says of signing with Nas’ Mass Appeal. “He is looking forward to working not just with me, but a lot of the young talent in India. I will be working with Mass Appeal India not just in a personal capacity, but also in my capacity as founder of Gully Gang Entertainment to help Mass Appeal India build a thriving ecosystem for urban music and culture in the sub-continent. So, let’s bring our A-Game because the world is watching,” he adds.
Adam Granite, EVP, Market Development, Universal Music Group, said, “For many years hip-hop, regardless of local language, has been growing rapidly around the world as the authentic sound of the streets. We are excited to work together with Nas, Peter, DIVINE, Devraj and the UMI team to launch Mass Appeal India, which we believe will become India’s premier dedicated hip-hop brand. The emergence of Mass Appeal India and the signing of Divine will only fuel the next wave of Indian hip-hop and rap talent and help accelerate the growth and reach of the genre in India, the subcontinent and beyond.”
DIVINE is currently working on his debut album, Kohinoor set to be released later this year.
Please click here for Video and Photo assets for DIVINE & Mass Appeal.
Watch the Interview with DIVINE and Nas to launch Mass Appeal India here:
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
